9 Oak Park Drive
303 articles with Insulet Corporation
Insulet Reports Fourth Quarter Revenue of $130.5 Million, Up 26%, and Gross Margin Up 210 Basis Points, Exceeding Expectations
Insulet Corporation today announced financial results for the three months and full year ended December 31, 2017.
Insulet Has Strong Presence at the International ATTD Congress; Presents Positive Study Results for Its Omnipod Horizon Hybrid Closed-Loop System
Insulet today announced promising new data for its Omnipod Horizon Automated Glucose Control System (Omnipod Horizon) hybrid closed-loop system, which will be presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) congress in Vienna, Austria.
The lawsuit alleged that Insulet misrepresented the success of its OmniPod Eros roll-out in 2013.
Insulet Corporation to Announce Fourth Quarter and Full Year 2017 Financial Results on February 21, 2018
Insulet today announced plans to release its financial results for the fourth quarter and full year of 2017 on February 21, 2018 after the close of the financial markets.
Ascensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by Signing Commercial Agreement
This follows the worldwide non-exclusive development agreement that Ascensia announced in June 2017 to connect its CONTOUR NEXT ONE BGMS with Insulet's next-generation Omnipod System.
Insulet today announced that the Centers for Medicare and Medicaid Services (CMS) has issued guidance clarifying that Medicare Part D Plan Sponsors may provide coverage for products such as the Omnipod System under the Medicare Part D (prescription drug) program.
Insulet Corporation announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 9, 2018, at 4:30pm (Pacific Time).
Insulet has priced a private placement of $350 million principal amount of convertible senior notes due 2024 (the Notes).
Insulet announced its intention to offer, subject to market and other conditions, $300 million principal amount of convertible senior notes due 2024 (the Notes) in a private placement.
Third quarter revenue of $121.8 million exceeds the Company's guidance of $112 to $116 million, a year-over-year growth of 28%.
Insulet Corporation Raises Awareness for Diabetes Community During National Diabetes Awareness Month
Earlier this year, Insulet announced that it will be establishing a direct local presence in Europe on July 1, 2018.
One of the growing areas in the medical device industry is new approaches to drug delivery.
Insulet is partnering with DexCom, Inc. (Dexcom) to provide the Omnipod System and a $200 gift card from Dexcom which can be used towards the purchase of a Dexcom G5 Mobile CGM (Continuous Glucose Monitoring) for qualified Animas insulin pump users.
Insulet Offers Welcome Program For Animas Users To Try Omnipod Insulin Management System At Zero Cost
Insulet Presents Real-World Clinical Data On The Use Of Its Omnipod Insulin Management System In Approximately 39,000 Patients Using A Cloud-Based Data Management System